Board Self-Assessment That Actually Improves Performance
Most biopharma boards conduct some form of annual self-assessment. Very few of them improve because of it.
The typical process looks like this: a questionnaire is distributed, directors complete it individually, results are aggregated and anonymized, a summary is presented at a board meeting, the chair says something measured about areas for continued focus, and the conversation moves on. Six months later, nothing has changed. The same dynamics that produced underperformance before the evaluation continue to produce it after. The exercise has served its compliance purpose — it can be cited in governance documents and investor presentations as evidence that the board takes accountability seriously — without producing accountability in any meaningful sense.
This is not a peripheral problem. In clinical-stage biopharma, where the board is one of the company's most important strategic assets, governance that is not improving is governance that is drifting. The cost is real, even when it is invisible.
Why Evaluations Fail to Change Anything
The gap between evaluation and improvement is not an accident. It reflects structural features of how most assessments are designed and processed.
The first problem is anonymization without accountability. The instinct to protect individual directors from the discomfort of identified feedback is understandable, but it systematically prevents the evaluation from producing the one outcome that would make it useful: a specific conversation with a specific person about a specific behavior. Aggregated, anonymized results produce aggregated, anonymous responses. No one owns the problem because no one is named.
The second problem is question design that measures satisfaction rather than performance. Most board questionnaires ask directors to rate how well the board is functioning on dimensions like information quality, meeting effectiveness, and strategic engagement — questions that surface general sentiment rather than identifying specific failure modes. Directors who are comfortable with the current dynamics will report that things are working well. Directors who are uncomfortable may not say so if the questionnaire gives them no clear language for doing it.
The third problem is the absence of external calibration. A board that evaluates itself using only its own internal perspective has no mechanism for knowing whether its self-perception is accurate. A board that believes it is providing effective oversight may not be — and the fact that all its members share that belief is not evidence that it is true. Without some external point of reference, self-assessment tends toward confirmation rather than discovery.
The fourth problem is disconnection from action. Even well-designed evaluations that surface genuine problems often end in the same place: a summary discussion that acknowledges the issue and defers resolution to undefined future improvement. The evaluation becomes a record of problems identified, not a driver of problems solved.
What a Genuine Assessment Process Looks Like
Building an evaluation process that actually produces improvement requires changing the design on each of these dimensions.
Start with explicit criteria. Before any questionnaire is distributed, the board should have agreed on what good governance looks like for the company at its current stage. These criteria should be specific enough to be evaluated honestly. Not "the board provides effective strategic guidance" — but "the board has reviewed the company's competitive positioning in the last six months," "individual directors are prepared to discuss the clinical data at each board meeting," "the board has dedicated time to succession planning for the CEO role." Criteria that are concrete enough to pass or fail are criteria that can drive improvement.
Evaluate contributions, not just processes. A board that evaluates only its collective functioning — meeting quality, agenda design, information flow — misses the most important variable: whether individual directors are contributing at the level the company requires. An effective evaluation includes a candid assessment of each director's engagement, preparation, and value-add. This does not require naming names in a group document, but it does require that the chair or lead independent director have access to information that allows individual conversations to happen.
Include external perspective. The strongest board evaluations involve at least one outside element — an interview-based process conducted by an independent governance advisor, a structured conversation with the CEO and senior management about how the board is experienced from the management side, or a benchmarking exercise against governance practices at comparable companies. Each of these creates information that the board cannot generate from its own self-report. The management perspective is particularly underused. Directors who believe they are providing useful strategic challenge may not know that management experiences their engagement as either absent or micromanaging — two failure modes that feel very different from inside the boardroom.
Build a closed-loop action process. Every issue surfaced in the evaluation should be assigned to a specific owner, given a specific resolution timeframe, and reviewed at the following meeting. If the evaluation identifies that board meeting packages are arriving too late for directors to prepare adequately, someone owns fixing it and the fix is verified. If the evaluation identifies that the audit committee is not engaging deeply enough with financial controls, the committee chair owns a response and the board reviews it. The evaluation becomes the first step in a process rather than the whole of it.
The Role of the Chair
The quality of a board self-assessment is largely a function of how the chair runs it.
A chair who treats the evaluation as a compliance exercise will produce a compliance result. A chair who treats it as a genuine opportunity to identify where the board is falling short — and who is willing to be included in that assessment, not exempted from it — creates a different kind of process and a different kind of conversation.
This requires the chair to model a specific posture: willingness to receive critical feedback, resistance to the defensive impulses that evaluation naturally triggers, and genuine curiosity about where the board's blind spots are. It also requires the chair to act on what the evaluation surfaces, which means having the conversations that most chairs prefer to defer.
In venture-backed biopharma, the chair is often also an investor-director — a position that creates its own complications. An investor-director who serves as chair is evaluating a governance process in which they are personally implicated, and the institutional interests of the fund may not align perfectly with the governance interests of the company. Where this tension exists, a lead independent director who owns the self-assessment process can provide a more credible foundation for honest evaluation.
Evaluating at Three Levels
The most useful framework for a biopharma board self-assessment operates at three distinct levels simultaneously.
The collective board. How is the board functioning as a decision-making body? Are the right topics reaching the agenda? Is information quality adequate for informed judgment? Is there genuine debate, or are discussions consistently convergent before they begin? Is the board spending its time appropriately across governance, strategy, and oversight functions, or is one dimension crowding out the others?
The committees. Are each of the board's committees doing substantive work, or are they conducting nominal reviews that do not add meaningful governance value? Is the audit committee engaging with financial controls at an appropriate level of rigor? Is the compensation committee making independent judgments about executive pay, or ratifying management's preferences? Is there a scientific advisory function — formal or informal — that gives the board access to expert perspective that is not filtered through management?
Individual directors. Is each director attending and preparing for meetings? Is each director's contribution to discussion substantive and relevant? Is the expertise represented on the board still matched to the company's current challenges — or has the company evolved while the board composition has remained static? Are any directors creating dynamics that impair the board's collective effectiveness?
These three levels interact. A board that functions poorly as a collective may be experiencing the downstream effects of individual underperformance. A board whose committees are ineffective may be reflecting agenda and process problems at the full-board level. Evaluating at all three levels simultaneously makes it possible to identify root causes rather than symptoms.
Frequency and Timing
An annual self-assessment is the standard, and it is a reasonable baseline. But it is not always sufficient.
A board that is navigating a material transition — a CEO change, a significant clinical milestone, a financing event, the addition of new directors — may benefit from a more targeted mid-cycle review. The question in these moments is not whether the board is functioning well in general, but whether its governance is adequate to the specific challenge at hand.
The timing of the annual assessment relative to the board's calendar also matters. An evaluation that concludes in November and whose results are processed in December produces action plans that are implemented — at best — in the following year. An evaluation timed to the first quarter, when the board is establishing priorities and the governance cycle is beginning, creates a tighter connection between assessment findings and operating rhythm.
Honest Self-Assessment as Institutional Culture
The goal of a board self-assessment is not a well-designed process — it is a board that is genuinely improving its governance capacity over time. The process is instrumental to that goal, and can be well-designed while still failing to achieve it.
What makes the difference, consistently, is whether the board has developed a culture in which honest assessment of its own performance is normal rather than threatening. Boards that have this culture treat the annual evaluation as one instance of an ongoing conversation — a conversation that also happens in the chair's individual check-ins with directors, in the candid post-meeting debrief, in the willingness to name a pattern of behavior that is affecting the board's effectiveness before it becomes entrenched.
This is a culture that is built slowly, through repeated demonstrations that honest feedback is welcomed rather than punished, and that the board's commitment to its own improvement is genuine rather than performative.
In clinical-stage biopharma, where the decisions made around the board table carry extraordinary stakes for patients, shareholders, and the scientific mission of the company, that commitment is not optional. It is part of what governance actually means.
Lawrence Fine is CEO of AGCP Farmacêuticos and has advised on governance structure and board effectiveness across life sciences and advanced materials companies.